Genocea Biosciences (GNCA) Trading 8.5% Higher
Genocea Biosciences Inc (NASDAQ:GNCA) traded up 8.5% during mid-day trading on Friday . The stock traded as high as $0.90 and last traded at $0.89. 3,227,054 shares traded hands during mid-day trading, an increase of 144% from the average session volume of 1,321,469 shares. The stock had previously closed at $0.82.
Several equities research analysts recently issued reports on the company. Zacks Investment Research cut Genocea Biosciences from a “buy” rating to a “hold” rating in a report on Wednesday, January 3rd. Piper Jaffray Companies reissued an “overweight” rating and issued a $5.00 target price on shares of Genocea Biosciences in a research note on Thursday, November 2nd. ValuEngine lowered shares of Genocea Biosciences from a “sell” rating to a “strong sell” rating in a research note on Tuesday, September 26th. Needham & Company LLC lowered shares of Genocea Biosciences from a “buy” rating to a “hold” rating in a research note on Tuesday, September 26th. Finally, Cowen reissued a “buy” rating and issued a $10.00 target price on shares of Genocea Biosciences in a research note on Tuesday, September 26th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and three have given a buy rating to the company. Genocea Biosciences currently has an average rating of “Hold” and an average price target of $6.25.
The company has a debt-to-equity ratio of 2.51, a current ratio of 1.55 and a quick ratio of 1.55. The company has a market capitalization of $25.60, a P/E ratio of -0.41 and a beta of 1.94.
A number of institutional investors and hedge funds have recently added to or reduced their stakes in GNCA. Schwab Charles Investment Management Inc. purchased a new position in Genocea Biosciences in the 2nd quarter worth approximately $257,000. Rhumbline Advisers purchased a new position in Genocea Biosciences in the 2nd quarter worth approximately $157,000. Bank of New York Mellon Corp lifted its stake in Genocea Biosciences by 594.6% in the 2nd quarter. Bank of New York Mellon Corp now owns 84,119 shares of the biotechnology company’s stock worth $439,000 after purchasing an additional 72,008 shares in the last quarter. Teachers Advisors LLC purchased a new stake in shares of Genocea Biosciences during the 2nd quarter valued at approximately $268,000. Finally, TIAA CREF Investment Management LLC purchased a new stake in shares of Genocea Biosciences during the 2nd quarter valued at approximately $404,000. 34.69% of the stock is currently owned by institutional investors and hedge funds.
About Genocea Biosciences
Genocea Biosciences, Inc, is harnessing the power of T cell immunity to develop vaccines and immunotherapies company. The Company uses its discovery platform, AnTigen Lead Acquisition System (ATLAS), to design vaccines and immunotherapies that act, in part, through T cell (or cellular) immune responses.
Receive News & Ratings for Genocea Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genocea Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.